These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23076292)

  • 1. Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease.
    Yamamoto S; Suzuki A; Sasaki H; Sekiguchi-Ueda S; Asano S; Shibata M; Hayakawa N; Hashimoto S; Hoshinaga K; Itoh M
    J Bone Miner Metab; 2013 Jan; 31(1):116-22. PubMed ID: 23076292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
    Olmos JM; Hernández JL; Llorca J; Nan D; Valero C; González-Macías J
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4491-7. PubMed ID: 23043189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
    Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM;
    J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney transplantation restored uncoupled bone turnover in end-stage renal disease.
    Kawarazaki H; Shibagaki Y; Kido R; Nakajima I; Fuchinoue S; Ando K; Fujita T; Fukagawa M; Teraoka S; Fukumoto S
    Clin Nephrol; 2012 Jul; 78(1):10-6. PubMed ID: 22732332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Efficacy and Renal Safety of Bisphosphonate Between Low-Dose/High-Frequency and High-Dose/Low-Frequency Regimens in a Late-Stage Chronic Kidney Disease Rat Model.
    Fujita R; Ota M; Sato D; Nakazawa D; Kimura-Suda H; Nakamura F; Shimizu T; Kobayashi H; Iwasaki N; Takahata M
    Calcif Tissue Int; 2020 Oct; 107(4):389-402. PubMed ID: 32671419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
    Ota M; Takahata M; Shimizu T; Kanehira Y; Kimura-Suda H; Kameda Y; Hamano H; Hiratsuka S; Sato D; Iwasaki N
    Osteoporos Int; 2017 Apr; 28(4):1481-1490. PubMed ID: 27933339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alkaline Phosphatase, iPTH and Bone Turnover Markers in Chinese Advanced Chronic Kidney Disease Patients.
    Liu Y; He Q
    Clin Lab; 2015; 61(7):839-43. PubMed ID: 26299086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineral and bone disorder after kidney transplantation: a single-center cohort study.
    Sun L; Wang Z; Zheng M; Hang Z; Liu J; Gao X; Gui Z; Feng D; Zhang D; Han Q; Fei S; Chen H; Tao J; Han Z; Ju X; Gu M; Tan R
    Ren Fail; 2023 Dec; 45(1):2210231. PubMed ID: 37183797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
    Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
    Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
    Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical parameters of bone turnover in kidney transplant recipients.
    Smalcelj R; Kusec V; Puretić Z; Mareković Z
    Wien Klin Wochenschr; 1998 May; 110(9):326-30. PubMed ID: 9629624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
    Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.
    Sprague SM; Bellorin-Font E; Jorgetti V; Carvalho AB; Malluche HH; Ferreira A; D'Haese PC; Drüeke TB; Du H; Manley T; Rojas E; Moe SM
    Am J Kidney Dis; 2016 Apr; 67(4):559-66. PubMed ID: 26321176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.